[go: up one dir, main page]

WO2021209493A3 - Moyens et procédés de prévention et de traitement d'infections - Google Patents

Moyens et procédés de prévention et de traitement d'infections Download PDF

Info

Publication number
WO2021209493A3
WO2021209493A3 PCT/EP2021/059643 EP2021059643W WO2021209493A3 WO 2021209493 A3 WO2021209493 A3 WO 2021209493A3 EP 2021059643 W EP2021059643 W EP 2021059643W WO 2021209493 A3 WO2021209493 A3 WO 2021209493A3
Authority
WO
WIPO (PCT)
Prior art keywords
preventing
methods
treating infections
infection
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2021/059643
Other languages
English (en)
Other versions
WO2021209493A2 (fr
Inventor
Andreas Voigt
Richard Dolph ANDERSEN
Karl Skriner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leopold GmbH
Solyplus GmbH
Original Assignee
Leopold GmbH
Solyplus GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leopold GmbH, Solyplus GmbH filed Critical Leopold GmbH
Priority to EP21724196.7A priority Critical patent/EP4135718A2/fr
Priority to CA3171226A priority patent/CA3171226A1/fr
Priority to JP2022562965A priority patent/JP2023522049A/ja
Priority to BR112022020717A priority patent/BR112022020717A2/pt
Priority to IL296364A priority patent/IL296364A/en
Priority to US17/918,679 priority patent/US20230346824A1/en
Priority to MX2022012940A priority patent/MX2022012940A/es
Priority to PCT/EP2021/079199 priority patent/WO2022135767A1/fr
Priority to US18/258,861 priority patent/US20240050366A1/en
Priority to EP21805842.8A priority patent/EP4267148A1/fr
Priority to CA3202259A priority patent/CA3202259A1/fr
Publication of WO2021209493A2 publication Critical patent/WO2021209493A2/fr
Publication of WO2021209493A3 publication Critical patent/WO2021209493A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0241—Containing particulates characterized by their shape and/or structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/736—Chitin; Chitosan; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/20—Organic compounds containing oxygen
    • C11D3/22—Carbohydrates or derivatives thereof
    • C11D3/221—Mono, di- or trisaccharides or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/20—Organic compounds containing oxygen
    • C11D3/22—Carbohydrates or derivatives thereof
    • C11D3/222—Natural or synthetic polysaccharides, e.g. cellulose, starch, gum, alginic acid or cyclodextrin
    • C11D3/227—Natural or synthetic polysaccharides, e.g. cellulose, starch, gum, alginic acid or cyclodextrin with nitrogen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/26—Organic compounds containing nitrogen
    • C11D3/32—Amides; Substituted amides
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/48—Medical, disinfecting agents, disinfecting, antibacterial, germicidal or antimicrobial compositions
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G4/00—Chewing gum
    • A23G4/06—Chewing gum characterised by the composition containing organic or inorganic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/275—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of animal origin, e.g. chitin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Birds (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Otolaryngology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition destinée à être utilisée dans la prévention d'une infection, ou le traitement d'une infection, ou le traitement d'une maladie provoquée par une infection, la composition comprenant un composé choisi dans le groupe constitué par le chitosane ou un sel de celui-ci, le galactose, le mannose, la caféine et toute combinaison de ceux-ci.
PCT/EP2021/059643 2020-04-15 2021-04-14 Moyens et procédés de prévention et de traitement d'infections Ceased WO2021209493A2 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
EP21724196.7A EP4135718A2 (fr) 2020-04-15 2021-04-14 Moyens et procédés de prévention et de traitement d'infections
CA3171226A CA3171226A1 (fr) 2020-04-15 2021-04-14 Moyens et procedes de prevention et de traitement d'infections
JP2022562965A JP2023522049A (ja) 2020-04-15 2021-04-14 感染を防止および処置する手段および方法
BR112022020717A BR112022020717A2 (pt) 2020-04-15 2021-04-14 Meios e métodos para previnir e tratar infecções
IL296364A IL296364A (en) 2020-04-15 2021-04-14 Means and methods for preventing and treating infections
US17/918,679 US20230346824A1 (en) 2020-04-15 2021-04-14 Means and methods of preventing and treating infections
MX2022012940A MX2022012940A (es) 2020-04-15 2021-04-14 Medios y metodos de prevencion y tratamiento de infecciones.
PCT/EP2021/079199 WO2022135767A1 (fr) 2020-12-22 2021-10-21 Moyens et méthodes de prévention, de traitement et de détection d'infections
US18/258,861 US20240050366A1 (en) 2020-12-22 2021-10-21 Means and methods of preventing, treating and detecting infections
EP21805842.8A EP4267148A1 (fr) 2020-12-22 2021-10-21 Moyens et méthodes de prévention, de traitement et de détection d'infections
CA3202259A CA3202259A1 (fr) 2020-12-22 2021-10-21 Moyens et methodes de prevention, de traitement et de detection d'infections

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063010423P 2020-04-15 2020-04-15
US63/010,423 2020-04-15
EP20216717 2020-12-22
EP20216717.7 2020-12-22

Publications (2)

Publication Number Publication Date
WO2021209493A2 WO2021209493A2 (fr) 2021-10-21
WO2021209493A3 true WO2021209493A3 (fr) 2022-01-20

Family

ID=75870575

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2021/059643 Ceased WO2021209493A2 (fr) 2020-04-15 2021-04-14 Moyens et procédés de prévention et de traitement d'infections

Country Status (1)

Country Link
WO (1) WO2021209493A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3218782A1 (fr) * 2021-05-12 2022-11-17 Henry Daniel Compositions et procedes de reduction de la charge d'un virus ou d'un micro-organisme dans la cavite buccale

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1251267A (zh) * 1998-10-16 2000-04-26 王海军 一种口香糖
US20050058744A1 (en) * 2002-01-03 2005-03-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Edible compositions capable of removing oral biofilm
EP1561460A1 (fr) * 2002-07-19 2005-08-10 ADVANCELL - Advanced In Vitro Cell Technologies Nanoparticules pour l'administration de principes actifs, procede d'elaboration des dites particules et composition les contenant
WO2005074947A2 (fr) * 2003-12-10 2005-08-18 Sd Pharmaceuticals, Inc. Compositions pharmaceutiques antivirales
WO2005107710A2 (fr) * 2004-05-06 2005-11-17 Ivrea Pharmaceuticals, Inc. Particules pour la liberation d'agents actifs
US20060004314A1 (en) * 2001-06-14 2006-01-05 Hemcon, Inc. Antimicrobial barriers, systems, and methods formed from hydrophilic polymer structures such as chistosan
WO2008105934A2 (fr) * 2006-09-22 2008-09-04 Oregon Biomedical Engineering Institute, Inc. Utilisation de chitosane pour inactiver des agents toxiques et pathogènes
WO2013172725A1 (fr) * 2012-05-18 2013-11-21 Uniwersytet Jagiellonski Utilisation d'un polymère de chitosane dans le traitement et la prévention des infections provoquées par des coronavirus
CN108991209A (zh) * 2018-10-03 2018-12-14 山东筑梦者生物科技有限公司 一种壳寡糖磷虾油夹心型凝胶糖果复合配方

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11248094B2 (en) 2017-10-12 2022-02-15 Solyplus Gmbh Crosslinking of biopolymers in a semi-solid state
ES2975184T3 (es) 2017-10-12 2024-07-03 Solyplus Gmbh Métodos de fabricación de polímeros masivos concentrados y homogéneamente humectados y aplicaciones de los mismos
EP4268812A3 (fr) 2017-10-12 2023-12-27 SolyPlus GmbH Procédé de traitement de biopolymères utilisant des combinaisons de solvants
MX2020003976A (es) 2017-10-12 2020-10-01 Solyplus Gmbh Procesamiento mecanico de biopolimeros.

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1251267A (zh) * 1998-10-16 2000-04-26 王海军 一种口香糖
US20060004314A1 (en) * 2001-06-14 2006-01-05 Hemcon, Inc. Antimicrobial barriers, systems, and methods formed from hydrophilic polymer structures such as chistosan
US20050058744A1 (en) * 2002-01-03 2005-03-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Edible compositions capable of removing oral biofilm
EP1561460A1 (fr) * 2002-07-19 2005-08-10 ADVANCELL - Advanced In Vitro Cell Technologies Nanoparticules pour l'administration de principes actifs, procede d'elaboration des dites particules et composition les contenant
WO2005074947A2 (fr) * 2003-12-10 2005-08-18 Sd Pharmaceuticals, Inc. Compositions pharmaceutiques antivirales
WO2005107710A2 (fr) * 2004-05-06 2005-11-17 Ivrea Pharmaceuticals, Inc. Particules pour la liberation d'agents actifs
WO2008105934A2 (fr) * 2006-09-22 2008-09-04 Oregon Biomedical Engineering Institute, Inc. Utilisation de chitosane pour inactiver des agents toxiques et pathogènes
WO2013172725A1 (fr) * 2012-05-18 2013-11-21 Uniwersytet Jagiellonski Utilisation d'un polymère de chitosane dans le traitement et la prévention des infections provoquées par des coronavirus
CN108991209A (zh) * 2018-10-03 2018-12-14 山东筑梦者生物科技有限公司 一种壳寡糖磷虾油夹心型凝胶糖果复合配方

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANDRES Y. ET AL: "Antibacterial Effects of Chitosan Powder: Mechanisms of Action", ENVIRONMENTAL TECHNOLOGY, vol. 28, no. 12, 1 December 2007 (2007-12-01), GB, pages 1357 - 1363, XP055867026, ISSN: 0959-3330, DOI: 10.1080/09593332808618893 *
BENHABILES M S ET AL: "Antibacterial activity of chitin, chitosan and its oligomers prepared from shrimp shell waste", FOOD HYDROCOLLOIDS, ELSEVIER BV, NL, vol. 29, no. 1, 14 February 2012 (2012-02-14), pages 48 - 56, XP028422216, ISSN: 0268-005X, [retrieved on 20120222], DOI: 10.1016/J.FOODHYD.2012.02.013 *
PERINELLI DIEGO ROMANO ET AL: "Chitosan-based nanosystems and their exploited antimicrobial activity", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 117, 1 May 2018 (2018-05-01), NL, pages 8 - 20, XP055868443, ISSN: 0928-0987, DOI: 10.1016/j.ejps.2018.01.046 *
SUN HYEONGDEOK ET AL: "Studies on the Drug Loading and Release Profiles of Degradable Chitosan-Based Multilayer Films for Anticancer Treatment", CANCERS, vol. 12, no. 3, 5 March 2020 (2020-03-05), CH, pages 593, XP055825006, ISSN: 2072-6694, DOI: 10.3390/cancers12030593 *
ZHENG MEI ET AL: "Intranasal Administration of Chitosan Against Influenza A (H7N9) Virus Infection in a Mouse Model", SCIENTIFIC REPORTS, vol. 6, no. 1, 1 September 2016 (2016-09-01), XP055830792, Retrieved from the Internet <URL:https://www.nature.com/articles/srep28729.pdf> DOI: 10.1038/srep28729 *

Also Published As

Publication number Publication date
WO2021209493A2 (fr) 2021-10-21

Similar Documents

Publication Publication Date Title
WO2022035911A3 (fr) Méthodes de traitement d&#39;infections à coronavirus par co-administration d&#39;un ligand de fkbp et d&#39;un agent antiviral
CA3257053A1 (fr) Compositions et procédés de prévention, de traitement, de suppression et/ou d&#39;élimination d&#39;infestations et d&#39;infections phytopathogènes
WO2020083971A3 (fr) Nouveaux composés anthelminthiques
JOP20200130A1 (ar) مركبات كرومان مونوباكتام لعلاج العدوى البكتيرية
NO20055722D0 (no) Antiseptiske preparater, fremgangsmater og systemer
WO2014165107A3 (fr) Dérivés du mannose pour le traitement d&#39;infections bactériennes
CO2019011264A2 (es) Nanosistemas que comprenden plata y antibióticos y su uso para el tratamiento de infecciones bacterianas
AU2020231934A8 (en) Compounds useful in HIV therapy
MX2021002719A (es) Cannabinoides para el tratamiento de infecciones grampositivas incluidas cepas bacterianas resistentes a antibióticos.
WO2018176093A8 (fr) Formulations d&#39;alcaloïde berbérine dans la prévention et/ou le traitement d&#39;une maladie infectieuse
PH12022553235A1 (en) Compound for the treatment of coronaviral infections
EP4606375A3 (fr) Composés antibactériens
BR112019018615A2 (pt) compostos antimicrobianos, composições e usos dos mesmos
MX2019011908A (es) Macrociclos de peptidos anti-bacterianos y uso de los mismos.
WO2022020353A3 (fr) Méthodes et compositions pour le traitement et la prévention d&#39;une infection par un coronavirus
WO2014179784A3 (fr) Potentialisateurs antimicrobiens
MX2021005740A (es) Novedoso compuesto como inhibidor de proteina quinasa, y composicion farmaceutica que comprende el mismo.
PH12019500242A1 (en) 9-aminomethyl minocycline compounds and uses thereof
WO2021209493A3 (fr) Moyens et procédés de prévention et de traitement d&#39;infections
MX2021005421A (es) Macrólidos de 13 miembros con sustitución cíclica en c10 y usos de los mismos.
MX2022012940A (es) Medios y metodos de prevencion y tratamiento de infecciones.
WO2015100448A3 (fr) Thérapie antimicrobienne multimodale
MX2021005423A (es) Macrolidos de 13 miembros sustituidos con c10-alquileno y usos de los mismos.
MX2018011095A (es) Compuestos de carbapenem.
WO2018140707A8 (fr) Combinaison synergique de thermolysine et d&#39;un agent antibactérien pour réduire ou éliminer les biofilms bactériens de surfaces

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21724196

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 3171226

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 202217058278

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2022562965

Country of ref document: JP

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112022020717

Country of ref document: BR

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021724196

Country of ref document: EP

Effective date: 20221115

ENP Entry into the national phase

Ref document number: 112022020717

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20221013